Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1

Conditions

Melanoma 7Leukemia, Myeloid, Acute 5Neoplasms 3Pathologic Complete Response 2Ovarian Neoplasms 2Myelodysplastic Syndromes 2Multiple Myeloma 2Fallopian Tube Neoplasms 2Wilms Tumor 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm, Residual 1Mesothelioma, Malignant 1Leukemia 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoma 1Carcinogenesis 1Brain Neoplasms 1

Interventions

Vincristine 16Cyclophosphamide 16Filgrastim 13Etoposide 12Doxorubicin 12Radiotherapy 11Carboplatin 10X-Rays 9Dactinomycin 9Specimen Handling 8Phantoms, Imaging 8Magnetic Resonance Spectroscopy 8Granulocyte Colony-Stimulating Factor 8Temozolomide 6Melphalan 6Ifosfamide 6Topotecan 5Peripheral Blood Stem Cell Transplantation 5Nuclear Medicine Department, Hospital 5Irinotecan 5Busulfan 5Biopsy 5sargramostim 4Stem Cell Transplantation 4Thiotepa 3Radiation 3Nivolumab 3Mesna 3Itraconazole 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Wilms Tumor × Monatide (IMS 3015) × Clear all
NCT01827137 2024-09-19

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Sellas Life Sciences Group

Phase 1/2 Completed
20 enrolled 9 charts
GenitourinaryPlasma cell

Multiple Myeloma, Wilms Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡